Anticoagulants

Phase 3Small molecule

Sanofi

Anticoagulants is one of 120 small molecule programs targeting Venous Thromboembolism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

119

Competitors

Pipeline

Status by Indication[3][1]

Indication

Venous ThromboembolismActive, not recruiting

StrokeActive, not recruiting

Intracerebral HemorrhageActive, not recruiting

Myocardial InfarctionActive, not recruiting

Intracranial HemorrhageNot yet recruiting

Venous ThromboembolismPreclinical

Active, not recruiting

StrokePreclinical

Active, not recruiting

Intracerebral HemorrhagePreclinical

Active, not recruiting

Myocardial InfarctionPreclinical

Active, not recruiting

Intracranial HemorrhagePhase 3

Not yet recruiting

Competition

Competitive Landscape

150 competitors in Stroke

#DrugCompanyPhaseTrials

Anticoagulants

Sanofi

Phase 3

1 2

Standard-Dose Rtpa

TThe George Institute

Phase 3

1 3

Zometa

Pfizer

Preclinical

1 4

Savella

AbbVie

Preclinical

1 5

Proamatine

Repatha

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Zantac 150

CChattem

Preclinical

1 9

Alka-Seltzer

AAbbott

Preclinical

1 10

Haldol

DDePuy Orthopaedics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Antithrombotic

NCT04347187

Q1 2027

Phase 3Not yet recruiting

Intracranial Hemorrhage

NCT04229758

Q4 2027

Recruiting

GIST

NCT02219984

Q1 2036

Recruiting

Venous Thromboembolism

NCT03881345

Clinical

Trials by Indication[1]

Atrial Fibrillation2 trials

Atrial Fibrillation: Risk and Benefits of Anti-coagulation in the Elderly

Completed·KKarolinska Institutet··NCT03828162·2,943 enrolled

Improving Stroke Prevention in Atrial Fibrillation Through Pharmacist Prescribing

Completed·UUniversity of Alberta·Phase 4·NCT03126214·79 enrolled

Intracerebral Hemorrhage1 trial

Intracerebral Hemorrhage Due to Oral Anticoagulants: Prediction of the Risk by Magnetic Resonance

Completed·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau··NCT02238470·1,000 enrolled

Myocardial Infarction1 trial

Targeting Investigation and Treatment in Patients With Type 2 Myocardial Infarction

Completed·UUniversity of Edinburgh·N/A·NCT05419583·60 enrolled

Coronary Artery Ectasia1 trial

Coronary Artery Ectasia in Elective Coronary Angiography : Predictors, Outcomes and Management

Completed·—·N/A·NCT03896321·79 enrolled

GIST1 trial

START-Register: Survey on Anticoagulated Patients Register

Recruiting·GGUALTIERO PALARETI··NCT02219984·15,410 enrolled

6 more indications

Stroke1 trial

Study of the Follow-up of Stroke Treated With Anticoagulants

Completed·—··NCT03292575·441 enrolled

Intracranial Hemorrhage1 trial

Restarting Anticoagulation After Traumatic Intracranial Hemorrhage

Not yet recruiting·UUniversity of Texas at Austin·Phase 3·NCT04229758·1,100 enrolled

Antithrombotic1 trial

REGistry of Long-term AnTithrombotic TherApy-2

Recruiting·NNational Medical Research Center for Cardiology, Ministry of Health of Russian Federation··NCT04347187·2,000 enrolled

Acute Coronary Syndrome1 trial

Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia

Completed· Sanofi logo

Sanofi·Phase 4·NCT02984982·206 enrolled

Venous Thromboembolism1 trial

Ongoing Registry of Treatment of Venous Thromboembolism

Recruiting·MMedalp Private Surgery Clinic··NCT03881345·5,000 enrolled

Multiple Myeloma1 trial

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Terminated·PPrECOG, LLC.·Phase 1/2·NCT00790842·63 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Anticoagulants. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anticoagulants compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anticoagulants. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sanofi

Anticoagulants

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q4 2027

Q1 2036

Trials by Indication[1]

Atrial Fibrillation2 trials

Intracerebral Hemorrhage1 trial

Myocardial Infarction1 trial

Coronary Artery Ectasia1 trial

GIST1 trial

Stroke1 trial

Intracranial Hemorrhage1 trial

Antithrombotic1 trial

Acute Coronary Syndrome1 trial

Venous Thromboembolism1 trial

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News